Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743543 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of SPG Block for PTSD
A Early Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT05743543: Completed Early Phase 1 study, sponsored by New York State Psychiatric Institute.
NCT05743543 is a Early Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05743543, a Early Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Some patients with Post Traumatic Stress Disorder (PTSD) respond only partially to medication. This study is a pilot study investigating whether blocking the SPG helps reduce the symptoms of PTSD. This study does not involve treatment with medications. It is a proof of principal study.
Primary Outcome
feasibility: number of participants completing the 8-week study
Interventions
- OTHER Sphenopalatine ganglion block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-05-28 |
| Est. Completion | 2023-06-01 |
| Phase | Early Phase 1 |
What the finished NCT05743543 record still lists
NCT05743543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Sphenopalatine ganglion block is the first listed.
NCT05743543 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05743543 about?
NCT05743543 is a clinical study titled "A Pilot Study of SPG Block for PTSD". Some patients with Post Traumatic Stress Disorder (PTSD) respond only partially to medication. This study is a pilot study investigating whether blocking the SPG helps reduce the symptoms of PTSD. This study does not involve treatment with medications. It is a proof of principal study.
What is the current status of trial NCT05743543?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2019-05-28. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT05743543?
The interventions under investigation include: Sphenopalatine ganglion block (OTHER).
Who is sponsoring clinical trial NCT05743543?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05743543's enrollment target sits among peer trials
6 1845th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI